KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Account Payables (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Account Payables for 7 consecutive years, with $5.7 million as the latest value for Q3 2020.

  • On a quarterly basis, Change in Account Payables rose 564.92% to $5.7 million in Q3 2020 year-over-year; TTM through Sep 2020 was $5.8 million, a 182.67% increase, with the full-year FY2019 number at $7.0 million, up 294.58% from a year prior.
  • Change in Account Payables was $5.7 million for Q3 2020 at Supernus Pharmaceuticals, up from -$182000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.3 million in Q4 2019 to a low of -$7.0 million in Q1 2020.
  • A 5-year average of $247736.8 and a median of -$380000.0 in 2016 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 937.63% in 2017, then crashed 1060.12% in 2018.
  • Supernus Pharmaceuticals' Change in Account Payables stood at $5.1 million in 2016, then crashed by 86.43% to $692000.0 in 2017, then plummeted by 1060.12% to -$6.6 million in 2018, then soared by 209.81% to $7.3 million in 2019, then dropped by 22.26% to $5.7 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Change in Account Payables are $5.7 million (Q3 2020), -$182000.0 (Q2 2020), and -$7.0 million (Q1 2020).